Beyond the Textbook brought to you by the Advanced clinical education and training team at BD. Follow and subscribe wherever you get your podcasts to stay up to date with the latest expert conversations in clinical practice. This podcast is on behalf of Becton Dickinson and Company. The opinions and techniques presented herein are for educational purposes only. And the decision of which technique to use in a particular interventional application should be made by the healthcare professional based on the individual facts and circumstances of the patient and previous medical experience. The participating healthcare professionals have been compensated by Becton Dickinson and Company to participate in this podcast. Welcome to Beyond the Textbook, the podcast where we explore real world clinical insights that go beyond guidelines to improve patient care. This is right therapy, right conversation, right system, a four-part podcast series focused on practical, patient-centered approaches to recurrent pleural effusion care. In this 2nd episode, moderator Doctor Argento is joined by Doctor Mohindra to discuss what it means to have the right conversation with patients facing recurrent pleural effusion. The discussion focuses on shared decision making across oncology and plural teams, especially when patients are symptomatic, overwhelmed, or navigating complex treatment decisions. Doctor Argento and Doctor Mohindra explore how clinicians can communicate options clearly, involve caregivers and care team partners, and help patients choose a treatment pathway that reflects their goals, priorities, and clinical reality. Welcome to a podcast series named Right Therapy, Right Conversation, Right System. This is going to be a four-episode series um where we discuss all aspects of management of recurrent pleural effusions. Welcome to episode 2 of our podcast. My name is Doctor Christine Argento. I'm an interventional pulmonologist at Johns Hopkins, and I'm being joined today by Doctor Nisha Mohindra, who is a medical oncologist at Northwestern University. We're gonna talk today about the right conversation, shared decision making across oncology and plural teams. Hi, Nisha. How are you? Good. Thanks for having me. Thank you so much for being part of this. I was fortunate enough to work with Doctor Mohindra for several years when I was at Northwestern, and she is a wonderful, um, a wonderful medical oncologist who has lots of knowledge about thorough disease as well. Thanks. No, it was great. I think it speaks to multidisciplinary care, so I'm excited to talk about this topic with you. Well, why don't we start by you giving us a sense of how often do your patients present to you with pleural disease or pleural effusions in general? Yeah, it's, you know, as a, as a thoracic medical oncologist, I think that this is often a presenting symptom for some of our advanced stage patients, so I see it quite a bit. And I think that it also becomes another issue as disease changes over time, whether it's recurrence or new sites of disease. So I would say at least 40% of my patients will have some kind of plural component that we need to address to their disease. 40%, that's incredible. Um, how do you get a sense that somebody is coming to you and you might have to check a chest X-ray or a CT looking for a pleural effusion in particular? You know, it helps when we know how they presented. So if they presented with a new diagnosis, they presented with a pleural effusion. Until we've gotten them on treatment, as we start to get to know each other, having them tell us about their symptoms and what's happening really helps us, but it's sometimes patients tell you when they come, and it's nice because we do have a very robust interventional pulmonology. A counterpart in our clinic that will come over with an ultrasound, but certainly an X-ray is another nice way to understand what's going on. Yeah, exactly. So, you know, if you have these patients and you're saying 40% of your patients at some point in their trajectory have a pleural effusion or some form of pleural disease. How do you start that conversation with them? Like, do you send everybody to get a thoracentesis, or is it only selected patients? Is there something that they tell you that sort of prompts you to get their pleural disease managed? Or do you start with some of the oncology therapies? Um, as a first line of defense or maybe some diuretics or whatnot. How does that work in oncology? Yeah, it's a great question. So I think I'll take it a step back. In thoracic oncology, we've gotten to know our patients a lot earlier, and that includes pre-surgery. So the neoadjuvant space where we're treating patients prior to them going to surgical resection. And I think that that is one distinct population where we'll see a pleural effusion after surgery, that we're trying to understand what the trajectory will be over time, as well as we are eager then to also start the remainder of that treatment course with adjuvant therapy. So that does become a shared conversation with our thoracic surgery group as well as symptoms and then understanding what the hope and thought is for that type of effusion over time. That is very distinct to then a stage 4 patient who comes in and presents with a malignant pleural effusion. And again, I think that what we think about is what are the characteristics of the disease that we're treating? What are the expectations of our treatment, and then how symptomatic and how quickly are these effusions re-accumulating. Um, and I think that these are new terms to patients as they come. They are already very overwhelmed with just the diagnosis of cancer, let alone thinking about how to think about symptoms that come along with the disease. No kidding. So when, I mean, when you're talking to them then about this pleural effusion, are you talking to them and are you letting them know that this is probably or possibly related to their cancer? And how do those conversations generally go? Like, what kind of information are you giving them and what do you tell them about next steps? So when we know it's a malignant pleural effusion, I think even educating your patient as to how that presence correlates to their symptoms, a lot of patients will say, it's just shoulder pain, it's just a discomfort or I feel a pressure in my chest when I sit in a sleep in a certain direction. I think it's helpful to Tell them that that could be related to their effusion and if those symptoms are changing, that's an indication to talk to us. Certainly what we hope is that with treatment, effective treatment, that we will continue to reduce the disease burden and have the effusion follow. But I think that one of the things that we need to start thinking about is having these conversations more upfront, not sequentially thinking about If this happens, then we'll deal with this. I think that, you know, thinking about symptoms and complications of disease are important to come uh to take place at the same time as you're thinking about treatment decisions. For sure. Is there, you know, from, from an interventional pulmonary perspective, you know, Doctor Gillespie in our first episode went through some of the decision points about how we decide to manage some of these effusions. From an oncology standpoint, do you guys have The same decision points, different ones, like how do you sort of talk to patients? Do you always send for a thoracentesis first? Um, do you think about pleurodesis or IPC management, or is that sort of more in the realm of the pulmonologist that's treating the patient? It's a good question. I think as the oncologist, you become the person that starts to lay out the menu, so to speak, of options and you become a trusted source of how to think through decisions. So I think the first thing I do Tell them the why. These are the symptoms you might be experiencing. The goal of what we're thinking about next is to reduce that. Whether that's you can sleep better at night, you're maybe having less pain, you might be able to avoid being in and out of the ER or the hospital. These are the things that we're hoping to achieve. One way I'm going to achieve that is just by treating your cancer, but there are other ways that we should also be thinking about managing this effusion. And they try to have it be that we can walk through the pros and cons. And I think Dr. Gillespie did a great job of walking through, thinking about not only patient factors, comorbidities, what's the performance status, but also their goals. What do they hope to achieve? Um, are they thinking about if they could have the opportunity for it to be a one-time procedure? Is that the right thing, if that could be achieved for their lung? Are they actually more comfortable thinking about an indwelling catheter? And do they have the support at home to, to, to do that? Um, I also think about the treatments I'm giving. I realize that now we're in the era of toxicities, skin toxicities, irritations in places that we haven't seen. So again, thinking about that. So I think it's a lot of what support, what are patient preferences, and then what is what is achievable for that patient and right for where they are in their in their physicality. Right. Do you got, do you have in oncology, is there a set of guidelines that you can refer to that try and help you? Do you refer to the pulmonary ones or do you, have you just sort of learned with experience over time and speaking with your colleagues, that kind of thing? Yeah, that's a great question. So, oncology has a number of guidelines for a number of things, but I think this is a place that has been more of a learning through colleagues. There isn't a singular guideline from an oncology perspective that helps us think through decision making. Certainly I recognize through The work of my pulmonary colleagues, there are guidelines that we should be really thinking about for this, but I've been really lucky to have colleagues in this space in clinic with me that will help guide the decision and help manage. I think as an oncologist, the other part that we need to do, while we may not stay as abreast of the guidelines from a plural perspective. is also to help guide what our colleagues need to know. If I'm in first line therapy with a targeted therapy, I might already know that the response may be quick and expected soon. Whereas if we're in third line therapy, stability is the best I hope to achieve, and that may make the conversation a little bit more tailored. That's perfect. You just led me into my next question. I was gonna ask you as an oncologist, like, how do you Decide a preference between, or maybe you don't have preferences, but between, let's say, pleurodesis and IPCs. Um, so do you, do you, does that matter to you? Do you need a catheter versus pleurodesis? Does You know, if your patient is on, let's say, um, an immunotherapy, would you say not want the inflammatory response that maybe a pleurodesis would perform or give you? Um, is there some, is there some decisions around that that makes a difference for you guys that we should know about? You know, Not per se. I'll say that because I do think that the patient preferences and their goals are actually the most paramount, plus the expertise from the pulmonologist. I will tell you that I've learned the most through the conversations of, I will Not likely recommend one or the other because I do think that's a decision that they should be making with the person doing the procedure. But I do think it's reasonable to lay out what options could be in pros and cons. Um, but I do think it has to be in the context also of what we hope to achieve for their disease, which is probably a conversation we need to enhance. So at different points. Along the journey, we're going to have very different goals and very different trajectories of what may come next. And I think having that together with your colleagues that are going to be caring for your patient is important so we can make the right decision. Yeah, I think that's so important. Are there like certain treatments, let's say that would decrease the, the blood counts, for example, um, where you would say the timing of any intervention, whether it's 30 cys or an IPC placement would matter? Um, is there a time when you should really avoid catheter placements, things like that? Yeah, there are certain regimens or patient populations where we know they will experience cytopenias. And it's not that we should avoid it. It may be that we think about how to time placement, but also how to support them with growth factors. Um I think there are 3 big buckets we think about for oncology, so targeted therapies can be often those that will achieve a response quickly and fast, and those are very different decisions than for what I think about, and they don't affect counts. We talked about immunotherapy and there could be a number of regimens where you either include chemo or you have dual immunotherapy. Again, I love that you brought up what should we be thinking about because we can have very hyperactive immune responses, not only from the cancer therapy itself, but then we can induce that with Whatever intervention we do. Yeah. And is there, are there different regimen, treatment regimens that you guys provide that will sort of exacerbate the effusion so that we know at least for a time, maybe the effusion will be much, uh, will be a much bigger problem than it was before. Yeah, we've seen with some of our um monoclonal antibodies by specific, there could be some inflammatory or third spacing component that leads to effusions and I think that's where it is important to get sampling, but also management because it's important for me to understand, am I treating through a toxicity or am I treating and now it's progression. I think there's a wave of new drugs coming and I think we're going to learn it together. So I think talking and communicating will be important. Absolutely. Do you Is there, are there any kind of patient populations that give you pause? So, Like, are you more concerned about infection? I mean, I would say a lot of your patients end up being considered immune compromised. Um, in those scenarios, do you worry, uh, about IPCs? Do you worry about pleurodesis? Do you worry about thoracentesis and just how we manage these effusions in general? Is there a concern about spreading the cancer if we're putting an IPC in place? Those kinds of things, do those come up? It comes up a lot from the patient perspective. If you're sticking a needle in and putting something in there, is it going to spread elsewhere? I think that is incredibly rare in most cancers. There are very few. Um, who do I have pause with? I think it's the people that are undersupported. Their performance status may be low, they're becoming more hectic and frail, skin breakdown. Um If you don't have the right support at home, I think an indwelling catheter is incredibly, it can be very cumbersome for a patient who is also struggling from a performance status standpoint. For sure. And then, uh, at least, you know, wherever I've worked, and I know you work with a lot of advanced practice providers, um, how do they sort of figure into this algorithm? Do they do a lot of the counseling with you? Is that something that we can, we can really sort of utilize them for and like empower them to be having these conversations with patients, or is this something that you do as a medical oncologist? I think it's a team. I mean, I, I, I feel really lucky that I have a strong team, um, and I think that it's The bringing up concerns to me like, Have you thought about this for this patient? or reinforcing a conversation. Again, a first time conversation is overwhelming, so it helps to have that continued message and that continued conversation. As well as they are, I think the pulse of symptoms for patients and concerns for patients between our physician visits. So I think it's an important aspect that they can look for symptoms that are telling us that we need to move one direction or the other, or be able to enhance and move a conversation forward that we started the prior visit. 100%. I, I think for me it's always been that I don't know the patients tell them so much more. I know they know they know much more about their social support, right, about their symptoms on. Sort of the regular, not just during our visits. It seems like they communicate with them on a regular basis, um, which is really nice that they have these relationships. Um, so for me, it seems like the APPs are just a really nice way. So do you, do your APPs get, get training and You know, a lot of knowledge about pleural effusions and pleural disease. I'm, I'm guessing they become quite savvy, um, since 40% of your patients, right, are, are having this at some point in their trajectory. Like I said, I think we are so lucky we have a multidisciplinary clinic, and I think the best ways we have learned is through conversations with our colleagues about a patient. That's how I've learned. Why would you do this and not that? It's so helpful. I think Dr. Gillespie really nicely alluded to the, do I expect the lung to expand? Again, from an oncologist standpoint, that's probably not a vantage point I'm able to provide well. Um, so I think it's, it's, it's been learning a lot through colleagues and and having incredible colleagues and just talking to your colleagues, just call them and ask because I think that oncologists are. are keeping up with a pace of knowledge that is incredibly exciting but overwhelming. And I would like us to say that we don't need to know it. We always need to know who knows what we need, what we don't know. And, and, and I think the one thing I would say from an oncology standpoint is when you think about pleural management, especially with a malignant pleural effusion, um, try to have those conversations up front. And and not sequentially when things are not moving the way you hoped they would have they would move. From the disease response. I love that you've emphasized sort of not delaying care when they, when a pleural effusion is sort of present, um, and, and especially the communication, I think in a multidisciplinary fashion. I think we can all learn from each other. And so having these conversations, you know, for us as well, it's not just that we know everything about pleural disease and the oncologists don't. No, we're learning from you as well, sort of what treatments are they on, what should we expect from their treatment regimen, um, what are you guys concerned about? I think it really helps that you guys serve essentially as their primary care provider during their oncologic care, right? So, um, that's been really critical and I love that you emphasize that so much. Any parting words that you have to say as we sort of wrap up this, this episode? Um I think it is that we need to be good at having upfront conversations, framing it around patient symptoms and goals, what we hope to achieve by using interventions from a patient standpoint of this may allow you more time away. From the facility, more time away from us. And then again, just that cross collaboration with the whole team, whether it's the interventional pulmonologists or the APPs or the other physicians that take care of our patients. From an oncology standpoint, we need to educate also on the fact that where are we in this treatment journey so that we're making the right decision. I love it. But with that, I'll say thank you so, so much. Um, I've truly loved our conversation, Doctor Muhindra. I learned from you every time as well. It's, um, it's truly a pleasure. It has been a pleasure. Thanks so much. Thank you so much for joining our episode. I hope you will join us for episode 3, Building a high functioning plural clinic from vision to workflow to sustainability with myself and Doctor Yona Stalter. Thank you for listening to this episode of Right Therapy, Right Conversation, Right System. We hope this conversation with Doctor Argento and Doctor Mohindra offered practical ways to support shared decision making, align teams, and help patients understand their options during a complex and often overwhelming point in care. Be sure to tune in to the next episode where Doctor Argento will be joined by Doctor Gestalter to discuss how to build the right system, a high functioning plural clinic that supports coordinated patient centered care. Thanks for being part of the BD Advanced Community. This podcast is intended for educational purposes only. Follow and subscribe so you never miss an episode. For more clinical education, visit advanced EDU.bd.com. We look forward to continuing the conversation in our next episode. BD and the BD logo are trademarks of Becton Dickinson and Company or its affiliates. Copyright 2026 BD all rights reserved.